title: Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study.
abstract: BACKGROUND
  In gastric cancer patients who have positive results for peritoneal lavage cytology the disease is defined as CY1, and classified as stage IV, and this population has generally suffered a dismal outcome. For this population, we had conducted a phase II trial, with the 2-year survival rate as the primary endpoint, to test the strategy of D2 dissection followed by chemotherapy with single-agent S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium). Forty-eight patients were enrolled, of whom 47 were found to have been eligible for analysis. The 2-year survival rate of 46 % exceeded our expectations.
  
  
  METHODS
  Further follow up was conducted to confirm whether radical surgery could be recommended for the CY1 population.
  
  
  RESULTS
  The 5-year overall and relapse-free survival rates were 26 and 21 %, respectively.
  
  
  CONCLUSIONS
  Gastrectomy with curative intent could be considered for patients with CY1 disease provided they are scheduled to receive effective postoperative chemotherapy.
authors.affiliation: Department of Surgery II, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan. ykodera@med.nagoya-u.ac.jp
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Kodera
authors.forename: Seiji
authors.initials: S
authors.lastname: Ito
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Mochizuki
authors.forename: Norifumi
authors.initials: N
authors.lastname: Ohashi
authors.forename: Chie
authors.initials: C
authors.lastname: Tanaka
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kobayashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kojima
authors.forename: Takanori
authors.initials: T
authors.lastname: Matsui
authors.forename: Ken
authors.initials: K
authors.lastname: Kondo
authors.forename: Michitaka
authors.initials: M
authors.lastname: Fujiwara
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D004338:Drug Combinations; D005500:Follow-Up Studies; D005743:Gastrectomy; D006801:Humans; D010094:Oxonic Acid / Q000627:therapeutic use; D010529:Peritoneal Cavity / Q000473:pathology*; D010533:Peritoneal Lavage; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D015996:Survival Rate; D005641:Tegafur / Q000627:therapeutic use
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid